Nctid:
NCT00000134
Payload:
{"hasResults"=>true, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D015658", "term"=>"HIV Infections"}, {"id"=>"D000163", "term"=>"Acquired Immunodeficiency Syndrome"}, {"id"=>"D017726", "term"=>"Cytomegalovirus Retinitis"}, {"id"=>"D012173", "term"=>"Retinitis"}, {"id"=>"D007153", "term"=>"Immunologic Deficiency Syndromes"}], "ancestors"=>[{"id"=>"D000086982", "term"=>"Blood-Borne Infections"}, {"id"=>"D003141", "term"=>"Communicable Diseases"}, {"id"=>"D007239", "term"=>"Infections"}, {"id"=>"D015229", "term"=>"Sexually Transmitted Diseases, Viral"}, {"id"=>"D012749", "term"=>"Sexually Transmitted Diseases"}, {"id"=>"D016180", "term"=>"Lentivirus Infections"}, {"id"=>"D012192", "term"=>"Retroviridae Infections"}, {"id"=>"D012327", "term"=>"RNA Virus Infections"}, {"id"=>"D014777", "term"=>"Virus Diseases"}, {"id"=>"D000091662", "term"=>"Genital Diseases"}, {"id"=>"D000091642", "term"=>"Urogenital Diseases"}, {"id"=>"D007154", "term"=>"Immune System Diseases"}, {"id"=>"D012164", "term"=>"Retinal Diseases"}, {"id"=>"D005128", "term"=>"Eye Diseases"}, {"id"=>"D012897", "term"=>"Slow Virus Diseases"}, {"id"=>"D015828", "term"=>"Eye Infections, Viral"}, {"id"=>"D015817", "term"=>"Eye Infections"}, {"id"=>"D003586", "term"=>"Cytomegalovirus Infections"}, {"id"=>"D006566", "term"=>"Herpesviridae Infections"}, {"id"=>"D004266", "term"=>"DNA Virus Infections"}], "browseLeaves"=>[{"id"=>"M10283", "name"=>"Infections", "relevance"=>"LOW"}, {"id"=>"M6368", "name"=>"Communicable Diseases", "relevance"=>"LOW"}, {"id"=>"M16355", "name"=>"Syndrome", "relevance"=>"LOW"}, {"id"=>"M3522", "name"=>"Acquired Immunodeficiency Syndrome", "asFound"=>"Acquired Immunodeficiency Syndrome", "relevance"=>"HIGH"}, {"id"=>"M18250", "name"=>"HIV Infections", "asFound"=>"Acquired Immunodeficiency Syndrome", "relevance"=>"HIGH"}, {"id"=>"M10199", "name"=>"Immunologic Deficiency Syndromes", "asFound"=>"Immunodeficiency Syndrome", "relevance"=>"HIGH"}, {"id"=>"M15008", "name"=>"Retinitis", "asFound"=>"Retinitis", "relevance"=>"HIGH"}, {"id"=>"M19939", "name"=>"Cytomegalovirus Retinitis", "asFound"=>"Cytomegalovirus Retinitis", "relevance"=>"HIGH"}, {"id"=>"M2593", "name"=>"Blood-Borne Infections", "relevance"=>"LOW"}, {"id"=>"M15558", "name"=>"Sexually Transmitted Diseases", "relevance"=>"LOW"}, {"id"=>"M17933", "name"=>"Sexually Transmitted Diseases, Viral", "relevance"=>"LOW"}, {"id"=>"M18640", "name"=>"Lentivirus Infections", "relevance"=>"LOW"}, {"id"=>"M15026", "name"=>"Retroviridae Infections", "relevance"=>"LOW"}, {"id"=>"M17522", "name"=>"Virus Diseases", "relevance"=>"LOW"}, {"id"=>"M15149", "name"=>"RNA Virus Infections", "relevance"=>"LOW"}, {"id"=>"M2876", "name"=>"Genital Diseases", "relevance"=>"LOW"}, {"id"=>"M2875", "name"=>"Urogenital Diseases", "relevance"=>"LOW"}, {"id"=>"M10200", "name"=>"Immune System Diseases", "relevance"=>"LOW"}, {"id"=>"M14999", "name"=>"Retinal Diseases", "relevance"=>"LOW"}, {"id"=>"M8271", "name"=>"Eye Diseases", "relevance"=>"LOW"}, {"id"=>"M15700", "name"=>"Slow Virus Diseases", "relevance"=>"LOW"}, {"id"=>"M18371", "name"=>"Eye Infections", "relevance"=>"LOW"}, {"id"=>"M18382", "name"=>"Eye Infections, Viral", "relevance"=>"LOW"}, {"id"=>"M6791", "name"=>"Cytomegalovirus Infections", "relevance"=>"LOW"}, {"id"=>"M9643", "name"=>"Herpesviridae Infections", "relevance"=>"LOW"}, {"id"=>"M7442", "name"=>"DNA Virus Infections", "relevance"=>"LOW"}, {"id"=>"T1721", "name"=>"Cytomegalovirus Retinitis", "asFound"=>"Cytomegalovirus Retinitis", "relevance"=>"HIGH"}, {"id"=>"T1720", "name"=>"Cytomegalic Inclusion Disease", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Infections", "abbrev"=>"BC01"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Symptoms and General Pathology", "abbrev"=>"BC23"}, {"name"=>"Urinary Tract, Sexual Organs, and Pregnancy Conditions", "abbrev"=>"BXS"}, {"name"=>"Immune System Diseases", "abbrev"=>"BC20"}, {"name"=>"Eye Diseases", "abbrev"=>"BC11"}, {"name"=>"Rare Diseases", "abbrev"=>"Rare"}]}, "interventionBrowseModule"=>{"meshes"=>[{"id"=>"D015774", "term"=>"Ganciclovir"}, {"id"=>"C092309", "term"=>"Ganciclovir triphosphate"}, {"id"=>"D017245", "term"=>"Foscarnet"}], "ancestors"=>[{"id"=>"D000998", "term"=>"Antiviral Agents"}, {"id"=>"D000890", "term"=>"Anti-Infective Agents"}, {"id"=>"D019384", "term"=>"Nucleic Acid Synthesis Inhibitors"}, {"id"=>"D004791", "term"=>"Enzyme Inhibitors"}, {"id"=>"D045504", "term"=>"Molecular Mechanisms of Pharmacological Action"}, {"id"=>"D018894", "term"=>"Reverse Transcriptase Inhibitors"}], "browseLeaves"=>[{"id"=>"M18331", "name"=>"Ganciclovir", "asFound"=>"Anastrozole", "relevance"=>"HIGH"}, {"id"=>"M340476", "name"=>"Ganciclovir triphosphate", "asFound"=>"Anastrozole", "relevance"=>"HIGH"}, {"id"=>"M19543", "name"=>"Foscarnet", "asFound"=>"Orlistat", "relevance"=>"HIGH"}, {"id"=>"M13647", "name"=>"Phosphonoacetic Acid", "relevance"=>"LOW"}, {"id"=>"M4314", "name"=>"Antiviral Agents", "relevance"=>"LOW"}, {"id"=>"M4214", "name"=>"Anti-Infective Agents", "relevance"=>"LOW"}, {"id"=>"M7951", "name"=>"Enzyme Inhibitors", "relevance"=>"LOW"}, {"id"=>"M20935", "name"=>"Reverse Transcriptase Inhibitors", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Anti-Infective Agents", "abbrev"=>"Infe"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}]}}, "resultsSection"=>{"moreInfoModule"=>{"pointOfContact"=>{"email"=>"cmeinert@jhsph.edu", "phone"=>"410-955-8198", "title"=>"Curtis Meinert, PhD", "organization"=>"Johns Hopkins University"}, "certainAgreement"=>{"restrictionType"=>"GT60", "piSponsorEmployee"=>false, "restrictiveAgreement"=>true}}, "adverseEventsModule"=>{"timeFrame"=>"1 year, 4 months", "eventGroups"=>[{"id"=>"EG000", "title"=>"Intravenous Foscarnet", "description"=>"intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day\n\nFoscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day", "otherNumAtRisk"=>88, "otherNumAffected"=>7, "seriousNumAtRisk"=>88, "seriousNumAffected"=>32}, {"id"=>"EG001", "title"=>"Intravenous Ganciclovir", "description"=>"intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day\n\nGanciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day", "otherNumAtRisk"=>93, "otherNumAffected"=>7, "seriousNumAtRisk"=>93, "seriousNumAffected"=>41}, {"id"=>"EG002", "title"=>"Combination Therapy", "description"=>"combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.\n\nGanciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day\n\nFoscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day", "otherNumAtRisk"=>93, "otherNumAffected"=>10, "seriousNumAtRisk"=>93, "seriousNumAffected"=>51}], "otherEvents"=>[{"term"=>"Hospitalizations", "stats"=>[{"groupId"=>"EG000", "numAtRisk"=>88, "numEvents"=>9, "numAffected"=>7}, {"groupId"=>"EG001", "numAtRisk"=>93, "numEvents"=>10, "numAffected"=>7}, {"groupId"=>"EG002", "numAtRisk"=>93, "numEvents"=>11, "numAffected"=>10}], "organSystem"=>"Infections and infestations", "assessmentType"=>"SYSTEMATIC_ASSESSMENT", "sourceVocabulary"=>"other"}], "seriousEvents"=>[{"term"=>"Neutropenia", "stats"=>[{"groupId"=>"EG000", "numAtRisk"=>88, "numEvents"=>86, "numAffected"=>32}, {"groupId"=>"EG001", "numAtRisk"=>93, "numEvents"=>95, "numAffected"=>41}, {"groupId"=>"EG002", "numAtRisk"=>93, "numEvents"=>107, "numAffected"=>51}], "organSystem"=>"Blood and lymphatic system disorders", "assessmentType"=>"SYSTEMATIC_ASSESSMENT", "sourceVocabulary"=>"serious"}, {"term"=>"Thrombocytopenia", "stats"=>[{"groupId"=>"EG000", "numAtRisk"=>88, "numEvents"=>28, "numAffected"=>14}, {"groupId"=>"EG001", "numAtRisk"=>93, "numEvents"=>19, "numAffected"=>8}, {"groupId"=>"EG002", "numAtRisk"=>93, "numEvents"=>40, "numAffected"=>15}], "organSystem"=>"Blood and lymphatic system disorders", "assessmentType"=>"SYSTEMATIC_ASSESSMENT", "sourceVocabulary"=>"other"}], "frequencyThreshold"=>"1"}, "outcomeMeasuresModule"=>{"outcomeMeasures"=>[{"type"=>"PRIMARY", "title"=>"Morbidity", "denoms"=>[{"units"=>"Participants", "counts"=>[{"value"=>"88", "groupId"=>"OG000"}, {"value"=>"93", "groupId"=>"OG001"}, {"value"=>"93", "groupId"=>"OG002"}]}], "groups"=>[{"id"=>"OG000", "title"=>"Intravenous Foscarnet", "description"=>"intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day\n\nFoscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day"}, {"id"=>"OG001", "title"=>"Intravenous Ganciclovir", "description"=>"intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day\n\nGanciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day"}, {"id"=>"OG002", "title"=>"Combination Therapy", "description"=>"combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.\n\nGanciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day\n\nFoscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day"}], "classes"=>[{"categories"=>[{"measurements"=>[{"value"=>"88", "groupId"=>"OG000"}, {"value"=>"93", "groupId"=>"OG001"}, {"value"=>"93", "groupId"=>"OG002"}]}]}], "paramType"=>"NUMBER", "timeFrame"=>"Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial", "description"=>"To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis.", "unitOfMeasure"=>"participants", "reportingStatus"=>"POSTED"}]}, "participantFlowModule"=>{"groups"=>[{"id"=>"FG000", "title"=>"Intravenous Foscarnet", "description"=>"intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day\n\nFoscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day"}, {"id"=>"FG001", "title"=>"Intravenous Ganciclovir", "description"=>"intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day\n\nGanciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day"}, {"id"=>"FG002", "title"=>"Combination Therapy", "description"=>"combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.\n\nGanciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day\n\nFoscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day"}], "periods"=>[{"title"=>"Overall Study", "milestones"=>[{"type"=>"STARTED", "achievements"=>[{"groupId"=>"FG000", "numSubjects"=>"89"}, {"groupId"=>"FG001", "numSubjects"=>"94"}, {"groupId"=>"FG002", "numSubjects"=>"96"}]}, {"type"=>"COMPLETED", "achievements"=>[{"groupId"=>"FG000", "numSubjects"=>"89"}, {"groupId"=>"FG001", "numSubjects"=>"94"}, {"groupId"=>"FG002", "numSubjects"=>"96"}]}, {"type"=>"NOT COMPLETED", "achievements"=>[{"groupId"=>"FG000", "numSubjects"=>"0"}, {"groupId"=>"FG001", "numSubjects"=>"0"}, {"groupId"=>"FG002", "numSubjects"=>"0"}]}]}], "recruitmentDetails"=>"December 1992"}, "baselineCharacteristicsModule"=>{"denoms"=>[{"units"=>"Participants", "counts"=>[{"value"=>"89", "groupId"=>"BG000"}, {"value"=>"94", "groupId"=>"BG001"}, {"value"=>"96", "groupId"=>"BG002"}, {"value"=>"279", "groupId"=>"BG003"}]}], "groups"=>[{"id"=>"BG000", "title"=>"Intravenous Foscarnet", "description"=>"intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day\n\nFoscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day"}, {"id"=>"BG001", "title"=>"Intravenous Ganciclovir", "description"=>"intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day\n\nGanciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day"}, {"id"=>"BG002", "title"=>"Combination Therapy", "description"=>"combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.\n\nGanciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day\n\nFoscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day"}, {"id"=>"BG003", "title"=>"Total", "description"=>"Total of all reporting groups"}], "measures"=>[{"title"=>"Age, Categorical", "classes"=>[{"categories"=>[{"title"=>"<=18 years", "measurements"=>[{"value"=>"0", "groupId"=>"BG000"}, {"value"=>"0", "groupId"=>"BG001"}, {"value"=>"0", "groupId"=>"BG002"}, {"value"=>"0", "groupId"=>"BG003"}]}, {"title"=>"Between 18 and 65 years", "measurements"=>[{"value"=>"89", "groupId"=>"BG000"}, {"value"=>"94", "groupId"=>"BG001"}, {"value"=>"96", "groupId"=>"BG002"}, {"value"=>"279", "groupId"=>"BG003"}]}, {"title"=>">=65 years", "measurements"=>[{"value"=>"0", "groupId"=>"BG000"}, {"value"=>"0", "groupId"=>"BG001"}, {"value"=>"0", "groupId"=>"BG002"}, {"value"=>"0", "groupId"=>"BG003"}]}]}], "paramType"=>"COUNT_OF_PARTICIPANTS", "unitOfMeasure"=>"Participants"}, {"title"=>"Sex: Female, Male", "classes"=>[{"categories"=>[{"title"=>"Female", "measurements"=>[{"value"=>"7", "groupId"=>"BG000"}, {"value"=>"6", "groupId"=>"BG001"}, {"value"=>"10", "groupId"=>"BG002"}, {"value"=>"23", "groupId"=>"BG003"}]}, {"title"=>"Male", "measurements"=>[{"value"=>"82", "groupId"=>"BG000"}, {"value"=>"88", "groupId"=>"BG001"}, {"value"=>"86", "groupId"=>"BG002"}, {"value"=>"256", "groupId"=>"BG003"}]}]}], "paramType"=>"COUNT_OF_PARTICIPANTS", "unitOfMeasure"=>"Participants"}, {"title"=>"Region of Enrollment", "classes"=>[{"title"=>"United States", "categories"=>[{"measurements"=>[{"value"=>"89", "groupId"=>"BG000"}, {"value"=>"94", "groupId"=>"BG001"}, {"value"=>"96", "groupId"=>"BG002"}, {"value"=>"279", "groupId"=>"BG003"}]}]}], "paramType"=>"NUMBER", "unitOfMeasure"=>"participants"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE3"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"RANDOMIZED", "maskingInfo"=>{"masking"=>"DOUBLE", "whoMasked"=>["PARTICIPANT", "INVESTIGATOR"]}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"FACTORIAL"}, "enrollmentInfo"=>{"type"=>"ACTUAL", "count"=>279}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1992-12"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2015-08", "completionDateStruct"=>{"date"=>"1995-03", "type"=>"ACTUAL"}, "lastUpdateSubmitDate"=>"2015-08-11", "studyFirstSubmitDate"=>"1999-09-23", "resultsFirstSubmitDate"=>"2015-06-15", "studyFirstSubmitQcDate"=>"1999-09-23", "lastUpdatePostDateStruct"=>{"date"=>"2015-09-14", "type"=>"ESTIMATED"}, "resultsFirstSubmitQcDate"=>"2015-08-11", "studyFirstPostDateStruct"=>{"date"=>"1999-09-24", "type"=>"ESTIMATED"}, "resultsFirstPostDateStruct"=>{"date"=>"2015-09-14", "type"=>"ESTIMATED"}, "primaryCompletionDateStruct"=>{"date"=>"1995-03", "type"=>"ACTUAL"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Morbidity", "timeFrame"=>"Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial", "description"=>"To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis."}]}, "oversightModule"=>{"oversightHasDmc"=>true}, "conditionsModule"=>{"conditions"=>["HIV Infections", "Acquired Immunodeficiency Syndrome", "Cytomegalovirus Retinitis"]}, "referencesModule"=>{"references"=>[{"pmid"=>"8540847", "type"=>"BACKGROUND", "citation"=>"Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol. 1996 Jan;114(1):23-33. doi: 10.1001/archopht.1996.01100130021004."}, {"pmid"=>"11305288", "type"=>"BACKGROUND", "citation"=>"Martin BK, Kaplan Gilpin AM, Jabs DA, Wu AW; Studies of Ocular Complications of AIDS Research Group. Reliability, validity, and responsiveness of general and disease-specific quality of life measures in a clinical trial for cytomegalovirus retinitis. J Clin Epidemiol. 2001 Apr;54(4):376-86. doi: 10.1016/s0895-4356(00)00294-8."}]}, "descriptionModule"=>{"briefSummary"=>"To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir.\n\nTo compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.", "detailedDescription"=>"CMV retinitis is the most common intraocular infection in patients with AIDS and is estimated to affect 35 to 40 percent of patients with AIDS. Untreated CMV retinitis is a progressive disorder, the end result of which is total retinal destruction and blindness. At the time of this trial, drugs approved by the United States Food and Drug Administration (FDA) for the treatment of CMV retinitis were ganciclovir (Cytovene) and foscarnet (Foscavir). Although most retinitis responds well to initial therapy with systemically administered drugs, given enough time, nearly all patients will suffer a relapse of the retinitis. Relapsed retinitis generally responds to reinduction and maintenance therapy, but the interval between successive relapses progressively shortens. The CRRT addressed the issue of the management of relapsed CMV retinitis.\n\nThe CRRT was a multicenter, randomized, controlled clinical trial comparing three regimens in patients with relapsed retinitis. Patients with AIDS and CMV retinitis that had relapsed or was nonresponsive to initial therapy were randomized to one of three regimens: (1) intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day; (2) intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day; and (3) combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT", "OLDER_ADULT"], "minimumAge"=>"18 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"inclusion criteria: Males and females eligible for the CRRT must have been age 18 years or older and have had AIDS and CMV retinitis. They must have had active CMV despite a minimum of 28 days of previous treatment with an anti-CMV drug. Furthermore, they must have had an absolute neutrophil count greater than or equal to 500 cells/µL, platelet count greater than or equal to 20,000 cells/µL, and a serum creatinine \\< 2.5 mg/dL in order to tolerate the drug regimens.\n\nexclusion criteria: history of intolerance to ganciclovir or foscarnet, history of therapy involving the combination of foscarnet and ganciclovir, unwillingness to practice appropriate birth control, active drug or alcohol abuse, media opacity, retinal detachment not scheduled for surgical repair"}, "identificationModule"=>{"nctId"=>"NCT00000134", "acronym"=>"CRRT", "briefTitle"=>"Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)", "organization"=>{"class"=>"OTHER", "fullName"=>"Johns Hopkins Bloomberg School of Public Health"}, "officialTitle"=>"Cytomegalovirus Retinitis Retreatment Trial", "orgStudyIdInfo"=>{"id"=>"NEI-33"}, "secondaryIdInfos"=>[{"id"=>"U10EY008057", "link"=>"https://reporter.nih.gov/quickSearch/U10EY008057", "type"=>"NIH"}, {"id"=>"U01AI027668", "link"=>"https://reporter.nih.gov/quickSearch/U01AI027668", "type"=>"NIH"}]}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"intravenous foscarnet", "description"=>"intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day", "interventionNames"=>["Drug: Foscarnet"]}, {"type"=>"ACTIVE_COMPARATOR", "label"=>"intravenous ganciclovir", "description"=>"intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day", "interventionNames"=>["Drug: Ganciclovir"]}, {"type"=>"ACTIVE_COMPARATOR", "label"=>"combination therapy", "description"=>"combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.", "interventionNames"=>["Drug: Ganciclovir", "Drug: Foscarnet"]}], "interventions"=>[{"name"=>"Ganciclovir", "type"=>"DRUG", "otherNames"=>["cytovene"], "description"=>"intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day", "armGroupLabels"=>["combination therapy", "intravenous ganciclovir"]}, {"name"=>"Foscarnet", "type"=>"DRUG", "otherNames"=>["foscavir"], "description"=>"intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day", "armGroupLabels"=>["combination therapy", "intravenous foscarnet"]}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Johns Hopkins Bloomberg School of Public Health", "class"=>"OTHER"}, "collaborators"=>[{"name"=>"National Eye Institute (NEI)", "class"=>"NIH"}, {"name"=>"National Institute of Allergy and Infectious Diseases (NIAID)", "class"=>"NIH"}, {"name"=>"Johns Hopkins University", "class"=>"OTHER"}, {"name"=>"University of Wisconsin, Madison", "class"=>"OTHER"}, {"name"=>"Baylor College of Medicine", "class"=>"OTHER"}, {"name"=>"Tulane University School of Medicine", "class"=>"OTHER"}, {"name"=>"Icahn School of Medicine at Mount Sinai", "class"=>"OTHER"}, {"name"=>"New York Presbyterian Hospital", "class"=>"OTHER"}, {"name"=>"New York University", "class"=>"OTHER"}, {"name"=>"Northwestern University", "class"=>"OTHER"}, {"name"=>"University of California, Los Angeles", "class"=>"OTHER"}, {"name"=>"University of California, San Francisco", "class"=>"OTHER"}, {"name"=>"University of California, San Diego", "class"=>"OTHER"}, {"name"=>"University of Miami", "class"=>"OTHER"}, {"name"=>"University of North Carolina, Chapel Hill", "class"=>"OTHER"}, {"name"=>"Memorial Sloan Kettering Cancer Center", "class"=>"OTHER"}], "responsibleParty"=>{"type"=>"PRINCIPAL_INVESTIGATOR", "investigatorTitle"=>"Curtis Meinert, PhD", "investigatorFullName"=>"Curtis Meinert", "investigatorAffiliation"=>"Johns Hopkins Bloomberg School of Public Health"}}}}
